ARS's Neffy Launch Generates $12.8M Q2 Sales but Heavy SG&A Drives Big Losses

ARS Pharmaceuticals, Inc. (NASDAQ: SBTX) - What's happening inside

ARS launched neffy commercially in the U.S. (first shipments Sept 2024) and has begun recognizing product revenue. The quarter shows clear commercial revenue traction but also heavy marketing and commercial build costs tied to the U.S. launch and the ALK collaboration.

Key facts & figures (as reported, in thousands unless noted)
- Total revenue (Q2 2025): $15,717 (Q2 2024: $500). Six months 2025: $23,690 (2024: $500).
- Product revenue, net (Q2 2025): $12,800; six months: $20,563.
- Revenue under collaboration agreements (Q2 2025): $2,594; six months: $2,804.
- Cost of goods sold (Q2 2025): $4,984; six months: $6,078.
- Research & development (Q2 2025): $4,035 (down vs Q2 2024 $6,896). Six months R&D: $6,987 (2024: $12,130).
- Selling, general & administrative (Q2 2025): $54,312 (Q2 2024: $8,944). Six months SG&A: $95,416 (2024: $16,902).
- Loss from operations (Q2 2025): $(47,614); six months: $(84,791).
- Other income, net (Q2 2025): $2,731. Net loss (Q2 2025): $(44,883); six months net loss: $(78,823).
- Net loss per share, basic & diluted (Q2 2025): $(0.46); six months: $(0.80). Weighted-average shares (Q2): 98,361,771.
- Cash and cash equivalents: $51,540; short-term investments: $188,590 - combined cash & short-term investments: $240,130.
- Accounts receivable, net: $25,126 (Dec 31, 2024: $8,175).
- Inventories, net: $22,112 (current $8,738 + long-term $13,374). Zero‑cost inventory held: $9.8M at June 30, 2025.
- Accounts payable & accrued liabilities: $44,264 (Dec 31, 2024: $22,841).
- Financing liability (ALK-related): $71,959 (reflects ALK upfront recharacterized as financing liability).
- Total assets: $313,472; total liabilities: $121,151; total stockholders' equity: $192,321 (accumulated deficit $(202,128)).
- Cash flow - operating activities (six months): $(80,334); investing provided $77,635 (maturities > purchases of short-term investments); financing provided $3,422; net cash change +$723; cash at period end $51,540.

Positive aspects (income statement and operations)
- Commercial launch is producing product revenue: $12.8M in Q2 and $20.6M YTD - meaningful shift from zero sales a year ago.
- Collaboration monetization: ALK partnership produced a large upfront (previously received $145M) and contributed milestone revenue and contract receipts; ALK also supports commercialization (co-promotion in U.S.).
- Strong liquidity position on the balance sheet: $240.1M in cash & short-term investments provides runway (company states sufficient for at least 12 months and management expresses belief it can support operations through ~three years under their plan).
- R&D spend declined vs prior year periods (R&D six months down ~42% vs 2024) as company transitions more spend to commercialization and post‑approval activities.
- Cost of goods still moderate as early sales are consuming previously capitalized/zero-cost inventory, which reduces immediate per‑unit COGS.

Negative aspects / risks shown in the income statement and notes
- Heavy SG&A: $54.3M in Q2 and $95.4M YTD - marketing/advertising and commercial build are driving steep losses and high operating burn.
- Substantial operating loss and widening net loss: $(47.6M) OP loss in Q2, $(84.8M) YTD; net loss $(78.8M) six months - launch investment is expensive and profitability remains distant.
- Operating cash burn remains large: $(80.3M) used in operations YTD, though partially offset by investing maturities; conversion of AR and inventories to cash is critical.
- Concentration and collection risk: Accounts receivable jumped to $25.1M and title agent accounts represent a large share of AR (disclosure shows Title Agent ~76% of AR at period end), meaning cash realization depends on third-party structures.
- Contractual commitments: unconditional raw material purchase obligations $57.6M; ALK co-promotion commitments $26.8M; corporate sponsorship $10.0M - these are real cash outflows ahead.
- Financing liability (ALK) $71,959 reflects accounting treatment of ALK upfront - it's not free cash and creates future obligations/complexity.
- Inventory reserve of $2.16M recorded and $9.8M zero-cost inventory exists - as zero‑cost inventory is consumed, future COGS economics will change and per-unit costs are expected to rise as true costs flow through.
- Ongoing legal and IP risks: litigation (Aptar suit) and EPO opposition to an epinephrine patent (EP '649) are active; adverse outcomes could affect costs or exclusivity.

What to watch next
- Revenue trajectory and gross margin evolution as zero‑cost inventory is depleted - expect COGS per unit to increase over time; watch gross margin trends quarterly.
- SG&A cadence and ROI on $20.9M Q2 advertising spend (Q2 advertising: $20.9M; six months: $31.9M) - sales lift vs sustained high marketing spend is the crucial metric.
- Collection of receivables and AR days - conversion of $25.1M AR to cash affects near‑term liquidity.
- Inventory consumption and reserve changes - monitoring whether inventory turns align with demand forecasts.
- ALK milestones, royalty receipts and the implications of the $71,959 financing liability on future cash flows.
- Legal/IP developments (Aptar suit; EPO opposition) - outcomes could affect manufacturing partners or exclusivity.
- Cash runway execution vs management's view (note: company statements reference both a 12‑month sufficiency and management's plan referencing ~three years) - reforecasting by management will be critical.

Bottom line - concise read
ARS is at a classic commercial-launch inflection: the business has moved from R&D expense into real product revenue ($12.8M in Q2) and benefits from a sizeable ALK partnership that bolstered liquidity, but the company is burning heavily on SG&A to build a U.S. commercial footprint. Liquidity today ($240.1M) is a comfort, but operating cash burn and sizable contractual commitments mean execution on sales conversion, AR collection and disciplined marketing spending are essential. Investors should monitor revenue growth, margin normalization as zero‑cost inventory runs out, AR conversion, and ALK milestone/royalty cadence - those items will determine whether the launch investment converts to a durable commercial business or continues to produce steep losses.

Data source: ARS Pharmaceuticals, Inc. Form 10‑Q for the quarter ended June 30, 2025 (figures reproduced from the filing).